Praluent’s Price Cut: Testing The Tech Model For Drug Pricing
It may be more accident than design, but Sanofi and Regeneron are applying a tried and true pricing model to Praluent. Just ask tech companies.
You may also be interested in...
Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.
Express Scripts expects to negotiate a lower price per patient for Amgen’s Repatha assuming the drug shows benefits in a 27,500-patient outcomes trial. Critics of the PBM and its practices, however, may help industry push back against the idea that greater benefit means lower prices.
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.